EFFICACY OF LOW-DOSE CYTARABINE-BASED REGIMEN(CAG) FOLLOWED BY AZACITIDINE FOR ELDERLY PATIENTS WITH MDS/AML

被引：0
|
作者：
Tabayashi, Takayuki [1 ]
Takahashi, Yasuyuki [1 ]
Kimura, Yuta [1 ]
Tomikawa, Tatsuki [1 ]
Sagawa, Morihiko [1 ]
Anan, Tomoe [1 ]
Watanabe, Reiko [1 ]
Tokuhira, Michihide [1 ]
Mori, Shigehisa [1 ]
Kizaki, Masahiro [1 ]
机构：
[1] Saitama Med Univ, Saitama Med Ctr, Dept Hematol, Saitama, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-21-1
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
    Faderl, Stefan
    Ravandi, Farhad
    Huang, Xuelin
    Wang, Xuemei
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Ferrajoli, Alessandra
    Konopleva, Marina
    Borthakur, Gautam
    Burger, Jan
    Feliu, Jennie
    Kantarjian, Hagop M.
    CANCER, 2012, 118 (18) : 4471 - 4477
  • [32] PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE
    Clissa, C.
    Finelli, C.
    Follo, M.
    Stanzani, M.
    Papayannidis, C.
    Curti, A.
    Paolini, S.
    Mongiorgi, S.
    Manzoli, L.
    Martinelli, G.
    Cocco, L.
    Cavo, M.
    HAEMATOLOGICA, 2013, 98 : 309 - 309
  • [33] Second-Line Low-Dose Cytarabine after First-Line Treatment with 5-Azacitidine in Elderly Patients with AML or High-Risk MDS Ineligible for Intensive Chemotherapy. A Retrospective Single Center Analysis
    Jakob, Christian
    Gunther, Benjamin
    Dittberner, Katharina
    Boger, Leonard
    Bleienheuft, Philipp
    Breywisch, Frank
    Rothmann, Frank
    Peinert, Stefan
    Maschmeyer, Georg
    BLOOD, 2015, 126 (23)
  • [34] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [35] Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS)
    Macdonald, D. A.
    Assouline, S. E.
    Brandwein, J.
    Kamel-Reid, S.
    Eisenhauer, E. A.
    Couban, S.
    Foo, A.
    Leber, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.
    Krug, Utz
    Knoblauch, Nicola
    Gerss, Joachim
    Schliemann, Christoph
    Wiebe, Stefanie
    Mueller-Tidow, Carsten
    Berdel, Wolfgang E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis
    Bouligny, Ian M.
    Maher, Keri R.
    BLOOD, 2021, 138
  • [38] Study of oral clofarabine plus low-dose cytarabine in previously treated AML and high-risk MDS patients at least age 60
    Smith, K. M.
    Estey, E.
    Pagel, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] TREATMENT OF DENOVO ACUTE MYELOGENOUS LEUKEMIA IN ELDERLY PATIENTS USING LOW-DOSE CYTARABINE
    TILLY, H
    CASTAIGNE, S
    SIGAUX, F
    DEGOS, L
    PRESSE MEDICALE, 1985, 14 (15): : 827 - 831
  • [40] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Kumar, R.
    Stone, R. M.
    Wierzbowska, A.
    Bernal del Castillo, T.
    Falantes, J.
    Delaunay, J.
    Sabloff, M.
    Voso, M. T.
    Kim, I.
    Ram, R.
    Gau, J. P.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 381 - 381
12345